Recent Updates
Recently added Catalysts
ANIK Negative Sentiment Score: 25/100

ANIKA (ANIK) ALERT: Bragar Eagel & Squire, P.C. Continues Investigating Anika Therapeutics, Inc. on Behalf of Anika Stockholders and Encourages Investors to Contact the Firm

Key Takeaway: Bragar Eagel & Squire, P.C. is investigating potential claims against Anika Therapeutics, Inc. on behalf of its stockholders. This comes after Anika's recent press release regarding the U.S. pivotal clinical trial of Hyalofast, which failed to meet its co-primary endpoints, leading to a significant drop in stock price. The investigation pertains to possible violations of federal securities laws and other business practices. Investors who suffered losses are encouraged to contact the firm for further information.

Market Sentiment Analysis

CONCERNS & RISKS

  • Anika's stock fell 27.42% following the announcement of clinical trial results.
  • The pivotal clinical trial did not meet its pre-specified co-primary endpoints.
  • High dropout rates and missed visits during COVID complicated the trial results.
  • Potential legal investigations may indicate serious concerns about the company's practices.

Full Press Release Details

Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Anika (ANIK) To Contact Him Directly To Discuss Their Options
If you purchased or acquired stock in Anika and would like to discuss your legal rights, call Bragar Eagel & Squire partner Brandon Walker or Marion Passmore directly at (212) 355-4648.
NEW YORK, Aug. 12, 2025 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, is investigating potential claims against Anika Therapeutics, Inc. (“Anika” or the “Company”) (NASDAQ:ANIK) on behalf of Anika stockholders. Our investigation concerns whether Anika has violated the federal securities laws and/or engaged in other unlawful business practices.
Click here to participate in the action.
On July 30, 2025, Anika issued a press release "announc[ing] topline results from its U.S. pivotal clinical trial of Hyalofast, a resorbable, hyaluronic acid scaffold used in conjunction with autologous bone marrow aspirate concentrate (BMAC) for cartilage repair." The press release stated that "[w]hile Hyalofast demonstrated consistent improvements in treated patients across all measures of pain and function relative to microfracture, the study did not meet its pre-specified co-primary endpoints. The study was likely impacted by both a higher subject dropout rate in the microfracture arm and missed visits during COVID. This resulted in missing data, which reduced the evaluable sample size and complicated the statistical analysis."
On this news, Anika's stock price fell $3.06 per share, or 27.42%, to close at $8.10 per share on July 30, 2025.
If you purchased or otherwise acquired Anika shares and suffered a loss, are a long-term stockholder, have information, would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Brandon Walker or Marion Passmore by email at investigations@bespc.com, by telephone at (212) 355-4648, or by filling out this contact form.  There is no cost or obligation to you.
About Bragar Eagel & Squire, P.C.:
Bragar Eagel & Squire, P.C. is a nationally recognized law firm with offices in New York, South Carolina, and California. The firm represents individual and institutional investors in commercial, securities, derivative, and other complex litigation in state and federal courts across the country. For more information about the firm, please visit www.bespc.com. Attorney advertising. Prior results do not guarantee similar outcomes.
Follow us for updates on LinkedIn, X, and Facebook, and keep up with other news by following Brandon Walker, Esq. on LinkedIn and X.
Contact Information:
Bragar Eagel & Squire, P.C.
Brandon Walker, Esq.
Marion Passmore, Esq.

Tags

Bragar Eagel & Squire

Frequently Asked Questions

Who can investors contact regarding Anika losses?

Investors who suffered losses in Anika can contact Brandon Walker or Marion Passmore.

What triggered the investigation into Anika Therapeutics?

The investigation was triggered by potential violations of federal securities laws by Anika.

What was the outcome of Anika's clinical trial for Hyalofast?

Anika's Hyalofast trial did not meet its co-primary endpoints, impacting stock price.

How much did Anika’s stock drop after the trial results?

Anika's stock fell by $3.06 per share, a decline of 27.42%.

Is there a cost for discussing claims with the law firm?

There is no cost or obligation to discuss these claims with Bragar Eagel & Squire.

Last updated: Aug 12, 2025